Voyager Therapeutics (VYGR) Consolidated Net Income (2014 - 2026)

Voyager Therapeutics has reported Consolidated Net Income for 13 years, with the latest figure at -$27.9 million in Q1 2026.

• Quarterly Consolidated Net Income rose 9.94% year-over-year to -$27.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$116.6 million (down 38.52% YoY) and the FY2025 annual result came in at -$119.7 million, down 85.58% from the prior year.
• Consolidated Net Income fell to -$27.9 million in Q1 2026 per VYGR's latest filing, from -$27.4 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at $124.0 million in Q1 2023 and troughed at -$34.0 million in Q4 2024.
• A 5-year average of -$7.3 million and a median of -$22.2 million in 2023 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2022 and 2023: Consolidated Net Income plunged 515.6% in 2022, then surged 681.85% in 2023.
• Over 5 years, Consolidated Net Income stood at -$23.6 million in 2022, then surged by 344.34% to $57.7 million in 2023, then plunged by 158.93% to -$34.0 million in 2024, then increased by 19.33% to -$27.4 million in 2025, then fell by 1.86% to -$27.9 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$27.9 million, -$27.4 million, and -$27.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.